RA2 Calls for a Single Endpoint for New Drug Approvals for Alzheimer's Disease
Read the Report
A Diverse Phase 2 Pipeline of Alzheimer's Drugs Promises New Innovations and New Challenges.
Read the Report
Will the next five years witness innovative medicines for Alzheimer’s? Is the health system ready?
Read the Report
How do we invest $1 billion
in a solution for Alzheimer's?
We are united by a simple but bold belief: it is possible to prevent and effectively treat Alzheimer’s disease within our lifetimes
Statement of Beliefs
We have heard some say that Alzheimer’s disease is an inevitable part of aging. Others have claimed that it simply cannot be prevented or effectively treated anytime soon. Still others believe that we simply cannot afford to do what it would take to stop the disease. They are all wrong.
As men and women of science, we are united by a simple but bold belief: It is possible to prevent and effectively treat Alzheimer’s disease within our lifetimes, but only if our nation does what is necessary:
- Set an aggressive goal of stopping Alzheimer’s disease by 2025, because it will focus the energies of the research community;
- Invest significant resources in Alzheimer’s disease research and innovation, because our commitment to cures must match the scale of the challenge;
- Institute reforms to accelerate the drug pipeline and deliver therapies to patients faster, because the ultimate goal of research is to bring help to those afflicted, and to prevent the disease from afflicting future generations.
If government, private industry, and the research community unite with a common goal and purpose backed with the necessary leadership, resources and incentives, the power of scientific research can be unleashed to unlock new possibilities, to deliver new cures – and to prevent and treat Alzheimer’s disease.
The Founding Members of ResearchersAgainstAlzheimer's will approve any variations of this language and will distribute any approved additions or revisions to all signers upon use. Any approved variations will reflect a broad consensus of the research and scientific community.
Members of the network will be expected to:
- Concur with and add their name to the ResearchersAgainstAlzheimer’s Statement of Beliefs;
- Act as an advocate for Alzheimer’s research in your home country and with international organizations;
- Attend ResearchersAgainstAlzheimer’s events when schedule and availability allow;
- Provide scientific expertise and insights to inform policy maker outreach as your schedule permits; and
- Share with us your ideas on what a national and global public policy strategy to increase research in Alzheimer’s should be
Paul Aisen, M.D.Founding Director of the University of Southern California Alzheimer's Therapeutic Research Institute
Marilyn Albert, Ph.D.Director of the Division of Cognitive Neuroscience in the Department of Neurology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Alzheimer's Disease Research Center
David Bennett, M.D.Robert C. Borwell Professor of Neurological Sciences and Director of the Rush Alzheimer's Disease Center
Jeff Cummings, M.D.Director of the Cleveland Clinic Lou Ruvo Center for Brain Health
Steve DeKosky, M.D.Aerts-Cosper Professor of Alzheimer's Research at the University of Florida College of Medicine
Rachelle Doody, M.D., Ph.D.Former Director, Alzheimer's Disease and Memory Disorders Center at Baylor College of Medicine
Howard Fillit, M.D.Executive Director, Alzheimer's Drug Discovery Foundation
David Holtzman, M.D.Chair, Department of Neurology, Washington University, St. Louis
Takeshi Iwatsubo, M.D., Ph.D.*Professor of Neuropathology at the School of Medicine, University of Tokyo
Bruce Lamb, Ph.D.Executive Director, Stark Neurosciences Research Institute, Indiana University
Simon Lovestone, Ph.D.*Professor of Translational Neuroscience, Department of Psychiatry - Medical Services Division, University of Oxford
David Morgan, Ph.D.CEO, Byrd Alzheimer's Institute, University of South Florida
Ron Petersen, M.D., Ph.D.Director, Mayo Alzheimer's Disease Research Center
Reisa Sperling, M.D.Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School
Rudy Tanzi, Ph.D.Director, Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease & Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
John Trojanowski, M.D., Ph.D.Co-Director, Center for Neurodegenerative Disease Research and Director of the Alzheimer's Disease Core Center of the University of Pennsylvania.
Michael Weiner, M.D.Professor in Residence in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco and Principle Investigator of the Alzheimer's Disease Neuroimaging Initiative
Affiliations are for identification purposes only and do not necessarily represent the endorsement of the affiliated institution.
* indicates the representative is serving as a strategic advisor to ResearchersAgainstAlzheimer’s
ResearchersAgainstAlzheimer’s (RA2) is a global coalition of Alzheimer’s researchers that advocate for research funding and policy reform to prevent and treat Alzheimer’s disease by 2025. Given the challenges facing Alzheimer’s patients, caregivers and healthcare professionals today, RA2 considers the development of a coordinated, global research strategy critical.
Alzheimer’s researchers from G20 countries and beyond support RA2. For example, in 2016, RA2 held meetings in Toronto, Canada and Kobe, Japan with global Alzheimer’s researchers to raise support for RA2’s advocacy efforts. Additionally, RA2 issued a statement in the summer of 2016 coinciding with the G7 Health Ministers’ meeting in Kobe, Japan, calling on the G7 to adopt a set of policies and actions in Alzheimer’s and Dementia research that drive:
- Research funding;
- Basic research;
- Clinical research and clinical trials;
- Open science and data sharing;
- Care delivery and support; and
- Risk reduction
We remain convinced that if government, private industry, and the research community unite with a common goal, backed with the leadership, resources and incentives, the power of scientific research can be unleashed to deliver new cures and prevent and treat Alzheimer’s disease.
To join RA2 as part of this global effort, please click here.